Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
J Clin Gastroenterol ; 55(1): 67-76, 2021 01.
Article in English | MEDLINE | ID: covidwho-1140031

ABSTRACT

BACKGROUND: The worldwide outbreak of COVID-19 infected millions of people. Some patients had gastrointestinal (GI) symptoms, abnormal liver function, digestive system disease and liver disease. AIM: To investigate the prevalence of GI symptoms, abnormal liver function, digestive system disease and liver disease in patients with COVID-19 by a systematic review and meta-analysis. METHODS: We searched PubMed, Ovid Embase, Medline, and 2 Chinese databases. Primary outcomes were the prevalence of GI symptoms, abnormal liver function, digestive system disease, and liver disease. Different studies were included in different subset analysis. These outcomes were estimated with proportions, odds ratio, 95% confidence interval (CI) and P-value by Stata SE 15.1. RESULTS: Thirty-one studies involving 4682 patients were included. The most significant GI symptoms were diarrhea (0.08, 95% CI: 0.06-0.11) and anorexia (0.17, 95% CI: 0.06-0.27). The most significant abnormal liver function was increased alanine aminotransferase (ALT) (0.25, 95% CI: 0.16-0.33). A total of 5% of the patients had digestive system disease (95% CI: 0.02-0.08). A total of 3% of the patients had liver disease (95% CI: 0.02-0.05). The prevalence of nausea and vomiting, diarrhea, abnormal liver function, digestive system disease, and liver disease was higher in Wuhan group. The prevalence of diarrhea was higher in non-China group. Patients in severe/intensive care unit group were more likely to have diarrhea, anorexia, abdominal pain increased aspartate aminotransferase, and increased ALT. CONCLUSION: The most significant GI symptoms were anorexia and diarrhea. The most significant abnormal liver function was increased ALT. Severe patients were more likely to have GI symptoms and abnormal liver function.


Subject(s)
/complications , Gastrointestinal Diseases/epidemiology , Gastrointestinal Diseases/virology , Liver Diseases/epidemiology , Liver Diseases/virology , /diagnosis , Gastrointestinal Diseases/diagnosis , Global Health , Humans , Liver Diseases/diagnosis , Prevalence
3.
Finance: Theory and Practice ; 24(5):6-14, 2020.
Article in English | WHO COVID | ID: covidwho-1094729

ABSTRACT

Small and medium-sized enterprises (SMEs) are vital drivers of China’s economy As in any other country, SMEs in China are exceptionally exposed to the devastating effects of the COVID-19 outbreak The aim of the paper is to assess the impact of the pandemic on SMEs in China and study the effectiveness of the government’s support for SMEs through the crisis The methodologies applied by the authors included the historical and logical method, the method of the rising from the abstract to the concrete, synthesis, comparative factor analysis, grouping and graphical methods, as well as a systematic and statistical approach The authors investigate the main policies and initiatives launched in support of smaller businesses and implemented by the People’s Bank of China, the Ministry of Finance, the National Development and Reform Commission, the Ministry of Industry and Information Technology, as well as by the two national regulatory authorities -- China Banking and Insurance Regulatory Commission and China Securities Regulatory Commission In this paper the authors analyze the direct and indirect support available to SMEs through financial institutions The study leads to the conclusions that the state support for SMEs has been effective and helped to avoid a sharp decline in production However, the spread of the disease in other countries may threaten the recovery of the Chinese economy

4.
J Med Internet Res ; 23(3): e26799, 2021 03 02.
Article in English | MEDLINE | ID: covidwho-1085135

ABSTRACT

BACKGROUND: In view of repeated COVID-19 outbreaks in most countries, clinical trials will continue to be conducted under outbreak prevention and control measures for the next few years. It is very significant to explore an optimal clinical trial management model during the outbreak period to provide reference and insight for other clinical trial centers worldwide. OBJECTIVE: The aim of this study was to explore the management strategies used to minimize the impact of the COVID-19 epidemic on oncology clinical trials. METHODS: We implemented a remote management model to maintain clinical trials conducted at Beijing Cancer Hospital, which realized remote project approval, remote initiation, remote visits, remote administration and remote monitoring to get through two COVID-19 outbreaks in the capital city from February to April and June to July 2020. The effectiveness of measures was evaluated as differences in rates of protocol compliance, participants lost to follow-up, participant withdrawal, disease progression, participant mortality, and detection of monitoring problems. RESULTS: During the late of the first outbreak, modifications were made in trial processing, participant management and quality control, which allowed the hospital to ensure the smooth conduct of 572 trials, with a protocol compliance rate of 85.24% for 3718 participants across both outbreaks. No COVID-19 infections were recorded among participants or trial staff, and no major procedural errors occurred between February and July 2020. These measures led to significantly higher rates of protocol compliance and significantly lower rates of loss to follow-up or withdrawal after the second outbreak than after the first, without affecting rates of disease progression or mortality. The hospital provided trial sponsors with a remote monitoring system in a timely manner, and 3820 trial issues were identified. CONCLUSIONS: When public health emergencies occur, an optimal clinical trial model combining on-site and remote management could guarantee the health care and treatment needs of clinical trial participants, in which remote management plays a key role.


Subject(s)
/epidemiology , Cancer Care Facilities/statistics & numerical data , Medical Oncology/statistics & numerical data , Beijing/epidemiology , Clinical Trials as Topic/methods , Clinical Trials as Topic/statistics & numerical data , Female , Humans , Male , Medical Oncology/methods , Retrospective Studies
5.
Preprint | SciFinder | ID: ppcovidwho-4201

ABSTRACT

A review Arbidol has a broad-spectrum antiviral activity, which has a significant role in the prevention and treatment of influenza virus and other respiratory viral infections As one of the most widely used antiviral drugs, it can significantly improve patients′ clin symptoms and vital signs, and ultimately improve the quality of life Currently, corona virus disease 2019 (COVID-19) has become a global pandemic, posing a major threat to the lives of people around the world Because of its broad spectrum antiviral effect, arbidol has huge potential and has been added to the diagnosis and treatment plan for combating the epidemic in China, and cooperated with other antiviral drug to bring good therapeutic effects to patients Therefore, based on the previous antiviral treatment of arbidol, the feasibility of arbidol for COVID-19, with a view to providing a reference for rational clin use were systematically reviewed in this article

6.
Preprint | SciFinder | ID: ppcovidwho-3575

ABSTRACT

A review At present, the diagnosis and treatment of corona virus disease 2019 (COVID-19) has entered a critical period The treatment of complex and changeable disease requires the cooperation of doctors, nurses and pharmacists Therefore, from the perspective of pharmaceutical service, this article introduced some important aspects to improve the treatment of COVID-19, including the formulation of pharmaceutical care standards, prescription and medical order review, remote pharmaceutical care for COVID-19, pharmaceutical care for COVID-19 patients in the hospital and science popularization of COVID-19 As an important part of the prevention and control of epidemic disease, clin pharmacy service has played an active role in ensuring the safety and effectiveness of patients′ medication, thereby making contribution to the effective control of the epidemic

7.
Preprint | SciFinder | ID: ppcovidwho-5250

ABSTRACT

A review A number of cases of pneumonia with unknown causes have been found in Wuhan, Hubei province since Dec 2019, which were later identified as the Novel coronavirus pneumonia (NCP) And the NCP was included in category B infectious diseases and controlled by measures for category A infectious diseases by National Health Commission (NHC) of the People′s Republic of China At the same time, the NHC has also released several versions of Prevention and Treatment Plan of the Pneumonia Caused by the 2019-nCoV, and in the latest fifth version of the plan, ribavirin was used for antiviral treatment for the first time Therefore, in order to provide theor evidence for ribavirin in the fight against novel coronavirus, this paper summarizes the efficays and safety of ribavirin in the treatment of SARS and MERS

8.
Emerg Microbes Infect ; 9(1): 2368-2378, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-910382

ABSTRACT

Managing recovered COVID-19 patients with recurrent-positive SARS-CoV-2 RNA test results is challenging. We performed a population-based observational study to characterize the viral RNA level and serum antibody responses in recurrent-positive patients and evaluate their viral transmission risk. Of 479 recovered COVID-19 patients, 93 (19%) recurrent-positive patients were identified, characterized by younger age, with a median discharge-to-recurrent-positive length of 8 days. After readmission, recurrent-positive patients exhibited mild (28%) or absent (72%) symptoms, with no disease progression. The viral RNA level in recurrent-positive patients ranged from 1.8 to 5.7 log10 copies/mL (median: 3.2), which was significantly lower than the corresponding values at disease onset. There are generally no significant differences in antibody levels between recurrent-positive and non-recurrent-positive patients, or in recurrent-positive patients over time (before, during, or after recurrent-positive detection). Virus isolation of nine representative specimens returned negative results. Whole genome sequencing of six specimens yielded only genomic fragments. 96 close contacts and 1,200 candidate contacts of 23 recurrent-positive patients showed no clinical symptoms; their viral RNA (1,296/1,296) and antibody (20/20) tests were negative. After full recovery (no longer/never recurrent-positive), 60% (98/162) patients had neutralizing antibody titers of ≥1:32. Our findings suggested that an intermittent, non-stable excretion of low-level viral RNA may result in recurrent-positive occurrence, rather than re-infection. Recurrent-positive patients pose a low transmission risk, a relatively relaxed management of recovered COVID-19 patients is recommended.


Subject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Betacoronavirus/isolation & purification , Clinical Laboratory Techniques/methods , Coronavirus Infections/diagnosis , Pneumonia, Viral/diagnosis , RNA, Viral/analysis , Adult , Betacoronavirus/genetics , Betacoronavirus/immunology , Coronavirus Infections/therapy , Coronavirus Infections/transmission , Female , Genome, Viral/genetics , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/therapy , Pneumonia, Viral/transmission , Recurrence , Whole Genome Sequencing , Young Adult
9.
Bosn J Basic Med Sci ; 2020 Sep 07.
Article in English | MEDLINE | ID: covidwho-745645

ABSTRACT

Peripheral blood lymphocyte count is shown to be decreased in patients with COVID-19 in the early stage of the disease. The degree of lymphocyte count reduction is related to COVID-19 severity and could be used as an indicator to reflect the disease severity. Our aim was to investigate the value of lymphocyte count in determining COVID-19 severity and estimating the time for SARS-CoV-2 nucleic acid test results to turn negative. We retrospectively analyzed clinical data of 201 patients with severe and critical COVID-19. The patients were admitted to the West Campus of Union Hospital of Tongji Medical College of Huazhong University of Science and Technology. The data included age, gender, chronic disease, lymphocyte count, and SARS-CoV-2 nucleic acid test results. The age of patients in critically ill group was higher than in severely ill group (p = 0.019). The lymphocyte count of critically ill patients was lower than of severely ill patients. The cutoff value of lymphocyte count to distinguish between the critically ill and the severely ill was 0.735 × 109/L (p = 0.001). The cutoff value of lymphocyte count for SARS-CoV-2 nucleic acid test results turning negative in severely and critically ill patients with chronic diseases (hypertension, diabetes, and coronary heart disease) was 0.835 × 109/L (p = 0.017). The cutoff value of lymphocyte count for SARS-CoV-2 nucleic acid test results turning negative in severely and critically ill male patients was 0.835 × 109/L (p < 0.0001). Lymphocyte count could be an effective indicator to predict COVID-19 severity. It may also be useful in determining the time for nucleic acid test results to turn negative in COVID-19 patients with underlying chronic diseases or male COVID-19 patients with severe and critical conditions.

10.
Transl Psychiatry ; 10(1): 268, 2020 08 04.
Article in English | MEDLINE | ID: covidwho-700320

ABSTRACT

Coronavirus disease 2019 (COVID-19) has been recognized as a global pandemic, and psychiatric institutions located in the epicenter of the epidemic in China are facing severe challenges in fighting the epidemic. This article presents the accumulated experience of the authors during the process of combating COVID-19 in a psychiatric hospital. The aim of this article is to provide a reference for psychiatric specialty hospitals and institutions that treat large populations of chronically ill patients in other parts of the world.


Subject(s)
Betacoronavirus , Coronavirus Infections/complications , Coronavirus Infections/prevention & control , Hospitals, Psychiatric , Infection Control/methods , Mental Disorders/complications , Pandemics/prevention & control , Pneumonia, Viral/complications , Pneumonia, Viral/prevention & control , China , Humans
11.
Acta Pharm Sin B ; 10(7): 1205-1215, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-88716

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, we identified an anticoagulation agent dipyridamole (DIP) in silico, which suppressed SARS-CoV-2 replication in vitro. In a proof-of-concept trial involving 31 patients with COVID-19, DIP supplementation was associated with significantly decreased concentrations of D-dimers (P < 0.05), increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients. In particular, all 8 of the DIP-treated severely ill patients showed remarkable improvement: 7 patients (87.5%) achieved clinical cure and were discharged from the hospitals while the remaining 1 patient (12.5%) was in clinical remission.

SELECTION OF CITATIONS
SEARCH DETAIL